Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
10th Anniversary of Biomedicines—Pathogenesis of Chronic Diseases: Current Treatments and...
share announcement

10th Anniversary of Biomedicines—Pathogenesis of Chronic Diseases: Current Treatments and Future Cures

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 1750

Special Issue Editor

Prof. Dr. Rodney R. Dietert

E-Mail Website
Guest Editor
Department of Microbiology and Immunology, Cornell University, Ithaca, NY 14853, USA
Interests: microbiome; disease prevention; systems biology; nutraceuticals (prebiotic and probiotics); immune protection; developmental programming; anti-aging/healthspan; food and drug toxicity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic diseases, often called noncommunicable diseases (NCDs), are the world’s number one killer. Several hundred of these diseases exist, with autoimmune diseases alone representing more than 100 distinct conditions. NCDs are a serious epidemic due, in part, to their extensive comorbidities. Using the origins and development of these diseases, mechanistic research contributes not only to our understanding of these diseases but also drives further development of current preventative strategies, therapies, and future cures. While NCDs are remarkably diverse in presentation, affecting virtually every tissue and organ of the body, their development has some common roots, such as the feature of unresolving inflammation. They form an interconnected web of disease, producing reduced quality of life and untimely death.

The range of topics considered for this Special Issue can include: 1) new insights into the nature of these diseases, 2) effective preventative strategies considering pathogenesis, 3) current therapeutic approaches, and 4) the direction of future cures for these chronic diseases. Even when a paper focuses on a single disease (e.g., asthma, diabetes, inflammatory bowel, Alzheimer’s disease, or a cardiovascular condition), we encourage authors to discuss the potential utility of their findings to additional related NCDs.

This Special Issue welcomes both original research and review papers that broaden our knowledge base and/or inform our efforts to blunt the NCD epidemic.

Prof. Dr. Rodney R. Dietert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pathogenesis
  • noncommunicable diseases
  • molecular pathways
  • metabolism
  • inflammation
  • microbiome
  • asthma and allergy
  • diabetes
  • depression
  • gastrointestinal disorders
  • cardiovascular disease
  • obesity
  • neurodevelopmental conditions
  • neurodegenerative conditions
  • autoimmune conditions

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1810 KiB  
Article
Cytokine Profile at Diagnosis Affecting Trough Concentration of Infliximab in Pediatric Crohn’s Disease
by Yiyoung Kwon, Eun-Sil Kim, Yoon-Zi Kim, Yon-Ho Choe and Mi-Jin Kim
Biomedicines 2022, 10(10), 2372; https://doi.org/10.3390/biomedicines10102372 - 23 Sep 2022
Cited by 3 | Viewed by 1294
Abstract
Background: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn’s disease and to determine if the initial tumor necrosis factor-alpha (TNF-α) level affected the [...] Read more.
Background: This study aims to measure the concentration of cytokines produced during the inflammation process to investigate if there are any differences in response to treatment of pediatric Crohn’s disease and to determine if the initial tumor necrosis factor-alpha (TNF-α) level affected the trough concentration of infliximab (IFX). Methods: This study included 30 pediatric patients with moderate-to-severe Crohn’s disease. At the time of diagnosis, blood samples were collected for the measurement of cytokines (IL-6, TNF-α, IL-17A, and IL-10). Blood samples were extracted from patients who had begun IFX treatment to measure the IFX trough concentration immediately before the fourth dose administration. Results: All cytokines (TNF-α, IL-6, IL-10, and IL-17A) were significantly higher in patients who did not achieve clinical or biochemical remission than in those who did (p = 0.027, 0.006, 0.017, 0.032, respectively). TNF-α had a negative correlation with the IFX trough concentration (Pearson coefficient = −0.425, p = 0.034). The diagnostic capability of the initial TNF-α concentration to predict under the therapeutic IFX trough concentration, defined as less than 3 µg/mL, had an area under the receiver operating characteristic of 0.730 (p = 0.049). The TNF-α concentration was set at 27.6 pg/mL as the cutoff value. Conclusions: Measuring cytokines at the time of diagnosis can be used to predict the treatment response. Measuring the initial TNF-α concentration may help to predict the treatment response to IFX. When the initial TNF-α concentration is greater than 27.6 pg/mL, a higher dose of IFX may be more appropriate than routinely administering 5 mg/kg of IFX to maintain the therapeutic concentration. Full article
(This article belongs to the Special Issue 10th Anniversary of Biomedicines—Pathogenesis of Chronic Diseases: Current Treatments and Future Cures)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop